IGC Pharma furnishes updated investor presentation on Alzheimer's agitation trial
IGC Pharma furnished an updated investor presentation dated July 2026 under Regulation FD, filed as Exhibit 99.1 to a Form 8-K dated July 13, 2026. The presentation covers the Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer's dementia, which the filing describes as investigational and not approved by the FDA, and it presents illustrative valuation scenarios that the company says are hypothetical and not forecasts.
Key points
- The CALMA Phase 2 trial has a target of 146 participants, and the presentation says more than 80% have completed dosing.
- The presentation cites a current valuation of about $30 million as of July 10, 2026, with illustrative post-Phase 2 scenarios of $350 million to $750 million over 4 to 9 months.
- Blinded pooled data show a mean change in CMAI of −13.6 at week 2 and −14.9 at week 6, which the company says cannot establish treatment effect or efficacy.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.